Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2011

01-07-2011 | Original Article

Detection of Intestinal Metaplasia After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation

Authors: Benjamin J. Vaccaro, Susana Gonzalez, John M. Poneros, Peter D. Stevens, Kristina M. Capiak, Charles J. Lightdale, Julian A. Abrams

Published in: Digestive Diseases and Sciences | Issue 7/2011

Login to get access

Abstract

Background

Radiofrequency ablation (RFA) is an effective means of eradicating Barrett’s esophagus (BE), both with and without associated dysplasia. Several studies have documented high initial success rates with RFA. However, there is limited data on IM detection rates after eradication.

Aims

To determine the rate of detection of intestinal metaplasia (IM) after successful eradication of Barrett’s esophagus.

Methods

BE patients with and without dysplasia who had undergone RFA were retrospectively identified. Only those who had complete eradication as documented on the initial post-ablation endoscopy, and had minimum two surveillance endoscopies, were included in the analyses. Clinical, demographic, and endoscopic data were collected. Cumulative incidence of IM detection was calculated by the Kaplan–Meier method.

Results

Forty-seven patients underwent RFA and had complete eradication of Barrett’s epithelium. The majority of patients were male (76.6%), and the mean age was 64.2 years. The cumulative incidence of newly detected IM at 1 year was 25.9% (95% CI 15.1–42.1%). Dysplasia was detected at the time of recurrence in four patients, and all cases were detected at the GE junction in the absence of visible BE. Patients with recurrent IM had longer baseline segments of BE (median, 4 cm vs. 2 cm, p = 0.03).

Conclusions

The rate of detection of new IM is high in patients who have undergone successful eradication of BE by RFA. Additionally, dysplasia can recur at the GE junction in the absence of visible BE. Future studies are warranted to identify those patients at increased risk for the development of recurrent intestinal metaplasia.
Literature
1.
go back to reference Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.PubMedCrossRef Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.PubMedCrossRef
2.
go back to reference Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23:451–457.PubMedCrossRef Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23:451–457.PubMedCrossRef
3.
go back to reference Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.PubMedCrossRef Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.PubMedCrossRef
5.
go back to reference Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.PubMedCrossRef Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.PubMedCrossRef
6.
go back to reference Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.PubMedCrossRef Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.PubMedCrossRef
7.
go back to reference Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol. 2007;102:1154–1161.PubMedCrossRef Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol. 2007;102:1154–1161.PubMedCrossRef
8.
go back to reference Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370–379.PubMedCrossRef Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370–379.PubMedCrossRef
9.
go back to reference Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–76. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–76.
10.
go back to reference Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781–789.PubMedCrossRef Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781–789.PubMedCrossRef
11.
go back to reference Halsey KD, Chang JW, Greenwald BD. Recurrent disease following endoscopic ablation of Barrett’s neoplasia. Gastroenterology. 2010;138:S17. Halsey KD, Chang JW, Greenwald BD. Recurrent disease following endoscopic ablation of Barrett’s neoplasia. Gastroenterology. 2010;138:S17.
12.
go back to reference Shaheen NJ, Fleischer DE, Eisen GM, et al. Durability of epithelial reversion after radiofrequency ablation: follow-up of the AIM Dysplasia Trial. Gastroenterology. 2010;138:S16. Shaheen NJ, Fleischer DE, Eisen GM, et al. Durability of epithelial reversion after radiofrequency ablation: follow-up of the AIM Dysplasia Trial. Gastroenterology. 2010;138:S16.
13.
go back to reference Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–1206.PubMedCrossRef Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–1206.PubMedCrossRef
Metadata
Title
Detection of Intestinal Metaplasia After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation
Authors
Benjamin J. Vaccaro
Susana Gonzalez
John M. Poneros
Peter D. Stevens
Kristina M. Capiak
Charles J. Lightdale
Julian A. Abrams
Publication date
01-07-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1680-4

Other articles of this Issue 7/2011

Digestive Diseases and Sciences 7/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.